For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Cannabis (medicinal) - Epilepsy
PAD Profile : Cannabis (medicinal) - Epilepsy Important
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Eslicarbazepine acetate
- Carbamazepine
- Clobazam
- Lacosamide
- Clonazepam
- Perampanel
- Ethosuximide
- Felbamate
- Rufinamide
- Gabapentin
- Stiripentol
- Lamotrigine
- Zonisamide
- Levetiracetam
- Oxcarbazepine
- Phenobarbital
- Piracetam
- Phenytoin
- Pregabalin
- Topiramate
- Sodium valproate
- Brivaracetam
- Sodium valproate
- Vigabatrin
- Cenobamate
- Primidone
- Tiagabine
Other Indications
Additional Documents
Committee Recommendations
NHS England guidance to support clinicians on the prescribing of cannabis-based products for medicinal use:
The Surrey & North West Sussex Area Prescribing Committee (APC) notes that NHS England routinely commissions cannabidiol for epilepsy in line with NICE TAs 614 and 615.
When cannabidiol is not being used in combination with clobazam, funding is via individual funding request (IFR) through NHS England.
Cannabidiol for epilepsy other than Lennox-Gastaut syndrome / Dravet syndrome: The APC confirmed that this would currently be an off-label / unlicensed use of a product with limited evidence for clinical efficacy or cost effectiveness. Clinicians who fulfil the legal criteria for the prescription of cannabidiol and who wish to prescribe it should check the responsible commissioner's Individual Funding Request (IFR) policy for more details.
PLEASE NOTE: only those centres commissioned to provide adult specialist neuroscience services or specialist neuroscience services for children should be prescribing cannabidiol for epilepsy. (See the specialised service letter SSC2111 (23rd December 2019) for further information and for lise of commissioned specialist centres).
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.